Sikiric et al., 2020b)
Semaglutide is officially approved for specific groups of people who meet certain criteria: For weight loss (Wegovy) Wegovy is approved for use in: Adults with a BMI 30 (obesity), or Adults with a BMI 27 (overweight) with at least one weight-related condition: Type 2 diabetes High blood pressure High cholesterol Sleep apnea Cardiovascular disease For Type 2 diabetes (Ozempic/Rybelsus) Ozempic and Rybelsus are approved for use in: Adults with type 2 diabetes who need better blood sugar control Those at high risk for cardiovascular events Patients who haven't achieved blood sugar goals with other medications Wegovy for heart health Wegovy is approved for use in: Adults with established cardiovascular disease who are overweight or obese People with type 2 diabetes with heart disease risk factors You might be a candidate for semaglutide if you: Have struggled with traditional diet and exercise alone Need to lose weight for health reasons Can commit to weekly injections (or daily pills for Rybelsus) Are willing to make lifestyle changes alongside medicationdiet and exercise are key Have realistic expectations about gradual weight loss Can afford long-term treatment (insurance coverage varies) Please consult your healthcare provider about whether semaglutide is right for you
And that's historically what I've been using
Comparing retatrutide to other GLP-1 options for women Retatrutide vs semaglutide and tirzepatide: the outcome gap Understanding where retatrutide fits in the current landscape of weight-loss pharmacology helps you evaluate whether it is the right choice for your situation and what to expect if you are transitioning from another medication
Heng YY, Asad I, Coleman B, Menard L, BenkiNugent S, Were FH, Karr CJ, McHenry MS (2022) Heavy metals and neurodevelopment of children in low and middle-income countries: a systematic review
You can enroll in an FSA during open enrollment, when youre hired or when you experience a status change, such as marriage or birth/adoption of a child
